T2 Biosystems Inc (TTOO) Actualités

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid...

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid...